10 results
P
lung disease, li, ipf
I/C
baicalin, no intervention
O
reduced inflammation, decreased apoptosis, protected against progression
P
patients with liver lesions
I/C
LI-RADS algorithm, original studies reporting probability of LR-M for HCC and non-HCC malignancy on MRI
O
pooled percentages of HCC and non-HCC malignancy for LR-M, sources of heterogeneity between reported results
P
Li QL, Yao MF, Cao RY, Zhao K, Wang XD
I/C
short dental implants, splinted and nonsplinted prostheses
O
survival rates
P
mouse models of IBD
I/C
Trichinella infection or derived antigens, control group
O
disease activity index (DAI), myeloperoxidase (MPO) activity, macroscopic inflammation score, microscopic inflammation score, anti-inflammatory cytokines (IL-4, TGF-β, IL-10, IL-13), proinflammatory cytokines (IFN-γ, IL-6, TNF-α, IL-17), regulatory T (Treg) cells, M1 phenotypic macrophage marker (iNOS), M2 phenotypic macrophage marker (Arg-1)
P
Individuals participating in blood flow restriction (BFR) training
I/C
BFR training, High-intensity resistance training (HIRT)
O
Muscular strength, hypertrophy, and endurance
P
red yeast rice preparations
I/C
RYR preparations, control treatments
O
adverse health outcomes
P
Orthodontic-surgical treatment patients
I/C
Conventional combined orthodontic-surgical treatment, No treatment or alternative treatments
O
Oral health-related quality of life
P
Dr. Heinrich, colleagues
I/C
systematic review and meta-analysis, the literature screening principles, outcome data collection, and the cohort studies included in the sub-group analysis
O
their review and suggestions
P
gynecologic and breast cancer survivors
I/C
oncology health professionals initiating and conducting open, honest discussions around sexual concerns with patients, availability of information in multiple forms, appropriate timing of information provision according to women's preferences
O
factors that prevent and/or facilitate gynecologic and breast cancer patients with sexual concerns seeking and accessing sexual health-related services
P
COVID-19 patients
I/C
3-drugs-3-formulas, conventional treatment
O
duration of fever, cough, fatigue, length of hospital stay, time for nucleic acid conversion, aggravation rate, mortality, recovery rate of chest computerized tomography manifestations, total effectiveness